Aaron Bensimon became the CEO of Genomic Vision Société Anonyme (EPA:GV) in 2006. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Then we'll look at a snap shot of the business growth. Third, we'll reflect on the total return to shareholders over three years, as a second measure of business performance. This process should give us an idea about how appropriately the CEO is paid.
Check out our latest analysis for Genomic Vision Société Anonyme
How Does Aaron Bensimon's Compensation Compare With Similar Sized Companies?
According to our data, Genomic Vision Société Anonyme has a market capitalization of €5m, and pays its CEO total annual compensation worth €267k. That's actually a decrease on the year before. We examined a group of similar sized companies, with market capitalizations of below €173m. The median CEO compensation in that group is €200k.
As you can see, Aaron Bensimon is paid more than the median CEO pay at companies of a similar size, in the same market. However, this does not necessarily mean Genomic Vision Société Anonyme is paying too much. A closer look at the performance of the underlying business will give us a better idea about whether the pay is particularly generous.
You can see a visual representation of the CEO compensation at Genomic Vision Société Anonyme, below.
Is Genomic Vision Société Anonyme Growing?
Over the last three years Genomic Vision Société Anonyme has shrunk its earnings per share by an average of 18% per year. Revenue was pretty flat on last year.
Sadly for shareholders, earnings per share are actually down, over three years. And the flat revenue hardly impresses. It's hard to argue the company is firing on all cylinders, so shareholders might be averse to high CEO remuneration.
Shareholders might be interested in this free visualization of analyst forecasts. .
Has Genomic Vision Société Anonyme Been A Good Investment?
Given the total loss of 92% over three years, many shareholders in Genomic Vision Société Anonyme are probably rather dissatisfied, to say the least. It therefore might be upsetting for shareholders if the CEO were paid generously.
In Summary...
We the total CEO remuneration paid by Genomic Vision Société Anonyme, and compared it to remuneration at a group of similar sized companies. We found that it pays well over the median amount paid in the benchmark group.
Neither earnings per share nor revenue have been growing sufficiently fast to impress us, over the last three years.Just as bad, share price gains for investors have failed to materialize, over the same period. This analysis suggests to us that the CEO is paid too generously! So you may want to check if insiders are buying Genomic Vision Société Anonyme shares with their own money (free access).
Of course, the past can be informative so you might be interested in considering this analytical visualization showing the company history of earnings and revenue.
To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.
The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.
Simply Wall St analyst Simply Wall St and Simply Wall St have no position in any of the companies mentioned. This article is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.